Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Epirubicin
Drug ID BADD_D00784
Description An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
Indications and Usage For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
Marketing Status approved
ATC Code L01DB03
DrugBank ID DB00445
KEGG ID D07901
MeSH ID D015251
PubChem ID 41867
TTD Drug ID D0C9XJ
NDC Product Code Not Available
UNII 3Z8479ZZ5X
Synonyms Epirubicin | 4'-Epidoxorubicin | 4' Epidoxorubicin | 4'-Epi-Doxorubicin | 4' Epi Doxorubicin | 4'-Epi-Adriamycin | 4' Epi Adriamycin | 4'-Epiadriamycin | 4' Epiadriamycin | 4'-Epi-DXR | 4' Epi DXR | EPI-cell | EPI cell | EPIcell | Epilem | Farmorubicina | IMI-28 | IMI 28 | IMI28 | NSC-256942 | NSC 256942 | NSC256942 | Ellence | Pharmorubicin | Farmorubicine | Farmorubicin | Epirubicin Hydrochloride | Hydrochloride, Epirubicin
Chemical Information
Molecular Formula C27H29NO11
CAS Registry Number 56420-45-2
SMILES CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.0020.000224%
Abdominal pain upper07.01.05.0030.000224%
Acute lymphocytic leukaemia01.10.01.001; 16.01.01.001---
Agranulocytosis01.02.03.001---
Alopecia23.02.02.0010.000560%
Amenorrhoea05.05.01.002; 21.01.02.001--
Anaemia01.03.02.0010.000224%
Anaphylactic shock10.01.07.002; 24.06.02.004---
Anuria20.01.03.002---
Anxiety19.06.02.0020.000526%
Aphthous ulcer07.05.06.0020.000112%-
Aplastic anaemia01.03.03.002---
Arrhythmia02.03.02.001---
Ascites02.05.04.002; 07.07.01.001; 09.01.05.003--
Asthenia08.01.01.0010.000616%-
Atrioventricular block02.03.01.002---
Azoospermia21.03.03.001--
Bladder stenosis12.02.10.011; 20.03.01.011---
Blister12.01.06.002; 23.03.01.001---
Blood lactate dehydrogenase increased13.04.02.002--
Blood uric acid increased13.02.04.001---
Body temperature increased13.15.01.001---
Bradycardia02.03.02.002---
Breast cancer16.10.01.001; 21.05.01.0030.000246%-
Bundle branch block02.03.01.009---
Burning sensation08.01.09.029; 17.02.06.001---
Cardiac failure02.05.01.0010.000280%
Cardiac failure congestive02.05.01.002---
Cardiomegaly02.04.02.001---
Cardiomyopathy02.04.01.001---
The 1th Page    1 2 3 4 5    Next   Last    Total 7 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene